Last reviewed · How we verify
Two vaccine injections DTP-pertussis-Hib
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis (whooping cough), and Haemophilus influenzae type b (Hib) bacteria.
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis (whooping cough), and Haemophilus influenzae type b (Hib) bacteria. Used for Prevention of diphtheria, Prevention of tetanus, Prevention of pertussis (whooping cough).
At a glance
| Generic name | Two vaccine injections DTP-pertussis-Hib |
|---|---|
| Sponsor | Central Hospital, Nancy, France |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxins from diphtheria and tetanus bacteria, acellular pertussis antigens, and Hib polysaccharide conjugate. Upon injection, these antigens trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize these pathogens upon future exposure. The two-injection series provides primary immunization against these four serious bacterial infections.
Approved indications
- Prevention of diphtheria
- Prevention of tetanus
- Prevention of pertussis (whooping cough)
- Prevention of Haemophilus influenzae type b infection
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: